Founder and Managing Director
Gregg applies more than 20 years of experience in the life science and technology industries, ranging from venture-backed start-ups to publicly traded companies. He previously served as CFO of two public and three privately held companies, during which time he managed finance, accounting, corporate communications, human resources, information technology, facilities, legal, intellectual property, business development and manufacturing functions. Gregg’s core expertise includes operational management, strategic planning and corporate and business development, fundraising and mergers and acquisitions. Prior to his CFO roles, Gregg was a life science investment banker with Adams, Harkness & Hill, where he underwrote financings for and provided buy- and sell-side M&A counsel to biotechnology, medical device, and healthcare information technology companies. He began his career as a corporate attorney with Gaffin & Krattenmaker, a Boston-based law firm. Gregg holds a BA from Middlebury College, JD from the University of Pittsburgh School of Law and MBA from Carnegie Mellon University.
Founder and Managing Director
Daniel brings more than 30 years of experience to his work for Danforth clients, ranging from start-ups to publicly traded companies with $1 billion+ market capitalizations. He has served as CFO and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, GenePeeks, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Since 2013, he has participated in seven initial public offerings. Over the course of his career, he has raised more than $1 billion in equity and debt securities for life science companies. Daniel holds a BS from The Wharton School, University of Pennsylvania, and MBA from Harvard Business School.
Steve has more than 30 years of experience in life sciences and healthcare, including founding two start-ups and working with venture-backed companies, subsidiaries of Fortune 100 firms and publicly traded companies. He previously served as CFO of two public companies and as CFO, COO, CEO or Director of eight privately held companies, in addition to his consulting clients. He has managed finance, accounting, corporate communications, human resources, information technology, facilities, business development, and manufacturing functions. Steve participated in the successful reorganization of Cambridge Biotech from Chapter 11 bankruptcy protection into Aquila BioPharmaceuticals, led the effort to take RXi public, and has extensive experience in international fundraising and corporate structuring. He was formerly Chairman of Cognoptix and is on the Board of Phytera, Inc. Steve’s core expertise includes operational management, strategic planning and corporate and business development, fundraising and mergers and acquisitions. He holds a BS from the University of Massachusetts and MBA from Babson College.
Bill joined Danforth in 2016 to build and lead the Healthcare Technology/Digital Health platform. As a passionate and seasoned CFO with over 25 years of strategic financial and operational management experience, Bill has successfully navigated several companies through rapid growth. His broad experience includes executive leadership with high growth and commercially driven healthcare technology and life science companies such as Humedica (sold to UnitedHealth), NaviNet (sold to Lumeris), SynapDx and ZappRx. Bill has led several successful M&A initiatives, including the highly strategic sale of Humedica to UnitedHealth in 2013. He is recognized for scaling, managing and leading rapidly growing health technology companies and has a successful history of financing via public/private equity transactions, raising more than $300 million. Bill holds a BA from Villanova University and MBA from the University of Massachusetts.
Director of Operations
Christine joined Danforth in 2015 to oversee operations, ranging from recruiting and staffing to administrative management and strategic projects that are core to the firm’s growth. She applies 20 years of finance management experience to the role, providing valuable perspective on how best to serve Danforth clients. Most recently, Christine worked as an independent financial consultant to both corporate and philanthropic organizations. She previously served as CFO of Young Innovations, Inc., a publicly traded medical device company. During her tenure, she identified, transacted and integrated several core acquisitions, led the company’s finance and accounting department, and worked closely with the executive management team and Board of Directors on the strategic options for the organization. Christine also spent six years in investment banking with Robert W. Baird, primarily focused on the healthcare and life science sectors. She began her career as a CPA with Deloitte & Touche in Boston. Christine holds a BA from Bowdoin College and an MBA from the University of Virginia Darden School of Business.
Managing Director, Mid Atlantic Region
Rob is an accomplished C-level executive with more than 20 years of experience leading life science and medical device companies, both private and public, ranging from early-stage development to commercial operations. Prior to joining Danforth, he served as CFO to multiple companies, including Motif Bio (NASDAQ/AIM: MTFB), Tyme Technologies, Inc. (NASDAQ: TYME), BeyondSpring Pharmaceuticals, Inc. (NASDAQ: BYSI) and NeoStem, Inc. – now Caladrius Biosciences, Inc. (NASDAQ: CLBS). He previously spent nearly 20 years in investment banking at Lehman Brothers and Legg Mason. Rob is experienced in all stages of the corporate lifecycle, including start-up operations, high growth, turnarounds and exit strategies. His expertise includes building organizations, public and private financings, M&A, partnering/licensing transactions, project management and Chapter 11 reorganizations, as well as interactions with boards, venture capitalists, shareholders and Wall Street. Rob holds an AB from Princeton University and MBA from The Wharton School, University of Pennsylvania.
Managing Director, Healthcare Services
Paul joined Danforth in January 2018 to expand the firm’s practice to the healthcare services sector. He is a proven leader of healthcare organizations, with nearly 30 years of experience in senior financial positions for both early- and mid-stage companies through periods of commercialization and growth. He continues to serve as CFO of PhysicianOne Urgent Care, a role for which he was named CFO of the Year by the Hartford Business Journal. He previously held senior leadership positions for Cambrooke Therapeutics, Shields Health Care Group and GE Healthcare, where he sold and subsequently integrated the business of ONI Medical Systems into the MRI business of GE Healthcare. Paul has extensive experience with a variety of private equity and debt financing strategies, and in managing all investor, bank and board of director relationships. He began his career at KPMG and holds a BS from Stonehill College.
Managing Director, New York Metro Region
Heather joined Danforth in 2015 with nearly 30 years of experience spanning private and public, start-up and later-stage organizations in the medical equipment and pharmaceutical industries. As an operational CFO, she has implemented strategic plans into corporate operations across functional areas including human resources, finance and accounting, research and development, manufacturing, quality, sales and marketing departments, while maintaining exceptional financial control and transparency to all stakeholders. Her Danforth clients have included Homology Medicines, Immuneering, Kallyope, Opsonix, Pear Therapeutics and SpringWorks Therapeutics, among others. Prior to joining Danforth, she held finance leadership roles for Cytonome and AutoImmune. Heather earned a BA from the University of California, San Diego, and MBA from the University of Michigan Graduate School of Business.
Managing Director, West Region
Jeff joined Danforth in 2017 to lead the firm’s growth in the western US, based in Colorado. He brings more than 25 years of experience to the role, both as a former investment banker and a strategic financial executive with expertise in operations and transactions for private and public companies. He previously held senior leadership positions for Great Basin Scientific, GlobeImmune, AlgoRx Pharmaceuticals and Antigenics, and later formed a successful life sciences financial advisory practice. He has raised more than $500 million for start-up companies and also led multiple liquidity events. Jeff began his career at Coopers & Lybrand and UBS Investment Bank, and holds a BS in Accounting from Case Western Reserve University.